Immunologic Factor
plerixafor
[ pleh-rik-suh-for ]
Brand Names:
Mozobil
Effect:
Increased Hematopoietic Stem Cell Mobilization
May Treat:
Lymphoma, Non-Hodgkin;
Multiple Myeloma
More Information:
Definitions related to plerixafor:
-
A bicyclam with hematopoietic stem cell-mobilizing activity. Plerixafor blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell (HSC) release from bone marrow and HSC movement into the peripheral circulation.NCI ThesaurusU.S. National Cancer Institute, 2021
-
A drug used before autologous stem cell transplantation in patients with non-Hodgkin lymphoma or multiple myeloma. Plerixafor is given together with granulocyte-colony stimulating factor (G-CSF) to help move stem cells from the bone marrow to the blood. The stem cells can then be collected, stored, and given back to the patient. Plerixafor is a type of chemokine receptor antagonist.NCI Dictionary of Cancer TermsU.S. National Cancer Institute, 2021
Return to OpenMD Medical Dictionary
> P
This content should not be used in place of medically-reviewed decision support reference material or professional medical advice. Some terms may have alternate or updated definitions not reflected in this set. The definitions on this page should not be considered complete or up to date.